Study Found Proteins in Urine Can Indicate Pancreatic Cancer

According to a recent study, published in Clinical Cancer Research, a journal of the American Association for Cancer Research, researchers have found three proteins in urine that indicate early stage pancreatic cancer. 

For the study, researchers analyzed 488 urine samples, including 192 from patients with pancreatic cancer, 92 from patients with chronic pancreatitis, and 87 from healthy people.  In addition, they looked at 117 urine samples from patients with diseases of the liver and gall bladder.  Of the 1,500 proteins found in the urine samples, the research team focused on three: LYVE1, REG1A and TFF1.  The researchers found that patients with pancreatic cancer had elevated levels of all three proteins compared with healthy patients and patients with pancreatitis.  Using all three proteins, they were able to detect early stage pancreatic cancer more than 90 percent of the time. 

“For a cancer with no early stage symptoms, it’s a huge challenge to diagnose pancreatic cancer sooner, but if we can, then we can make a big difference to survival rates,” said Nick Lemoine, Director of Barts Cancer Institute at Queen Mary University in London.  “With pancreatic cancer, patients are usually diagnosed when the cancer is already at a terminal stage, but if diagnosed at stage 2, the survival rate is 20 percent, and at stage 1, the survival rate for patients with very small tumors can increase up to 60 percent.” 

The clinical team at Columbus CyberKnife treats pancreatic cancer with the CyberKnife® Robotic Radiosurgery System.  CyberKnife delivers high doses of radiation directly to pancreatic tumors.  The system offers patients who cannot undergo pancreatic cancer surgery due to their poor medical condition, or who refuse surgery, a painless, noninvasive alternative treatment for pancreatic cancer.  CyberKnife treatments are typically performed on an outpatient basis in one to five days, requiring no overnight hospital stay, and most patients experience minimal to no side effects with a quick recovery time.  

For more information about how Columbus CyberKnife treats pancreatic cancer, please click here

Treating Pancreatic Cancer with CyberKnife Technology

According to the Pancreatic Cancer Action Network, a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer, pancreatic cancer has the highest mortality rate of all major cancers.  It is also one of the few cancers for which survival has not improved substantially over nearly 40 years. 

Pancreatic cancer is difficult to diagnose because patients usually don’t display symptoms until the cancer has progressed and spread to other parts of the body.  Common early symptoms include loss of appetite, mild weight loss and mild discomfort in the upper abdomen or occasionally in the middle-back.  Because these symptoms can be attributed to any number of conditions, early signs are often ignored or missed. 

Treatment for pancreatic cancer can be a curative or palliative approach involving surgery, radiation therapy, chemotherapy, stereotactic radiosurgery or a combination.  Due to side effects and complications associated with surgery for pancreatic cancer patients, stereotactic radiosurgery can be a safe, noninvasive option. 

Columbus CyberKnife treats pancreatic tumors with stereotactic radiosurgery using the CyberKnife® Robotic Radiosurgery System.  During treatment, high doses of radiation are delivered to the tumor with sub-millimeter accuracy.  Treatments are painless, require no anesthesia or hospital stay, and there is little to no recovery time. 

For more information on CyberKnife technology, or to make an appointment with Columbus CyberKnife, please click here